ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028
TABLE
OF CONTENTS
1. ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – SUMMARY
2. INDUSTRY
OUTLOOK
2.1. TIMELINE
OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.2. PHASES
AND STERNNESS OF ALZHEIMER’S DISEASE
2.3. KEY
INSIGHTS
2.3.1. USAGE
OF COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE
2.3.2. R&D
INVESTMENTS IN BIOMARKERS FOR EARLY DETECTION OF DEMENTIA
2.3.3. DEMAND
FOR PERSONALIZED MEDICINES
2.4. IMPACT
OF COVID-19 ON THE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.5. PORTER’S
FIVE FORCES ANALYSIS
2.6. MARKET
ATTRACTIVENESS MATRIX
2.7. VENDOR
SCORECARD
2.8. INDUSTRY
COMPONENTS
2.8.1. RESEARCH
& DEVELOPMENT (R & D)
2.8.2. RAW
MATERIALS
2.8.3. MANUFACTURING
2.8.4. DISTRIBUTORS/WHOLESALERS/RETAILERS
2.8.5. END-USER
2.9. KEY
IMPACT ANALYSIS
2.9.1. EFFECTIVENESS
2.9.2. PRICE
2.9.3. SAFETY
2.10. KEY
MARKET STRATEGIES
2.10.1. ACQUISITIONS
2.10.2. PRODUCT
LAUNCHES
2.10.3. CONTRACTS
& AGREEMENTS
2.10.4. INVESTMENTS
& EXPANSIONS
2.11. MARKET
DRIVERS
2.11.1. PREVALENCE
OF ALZHEIMER’S DISEASE
2.11.2. RISE
IN THE ELDERLY POPULATION
2.12. MARKET
CHALLENGES
2.12.1. FAILURE
OF LATE-STAGE DRUGS
2.12.2. STRINGENT
GOVERNMENT REGULATIONS
2.13. MARKET
OPPORTUNITIES
2.13.1. EMERGENCE
OF NEW DIAGNOSTIC TECHNOLOGIES
2.13.2. GROWING
NUMBER OF PIPELINE DRUGS
3. ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY THERAPEUTICS
3.1. BY
DRUG TYPE
3.1.1. MARKETED
DRUGS
3.1.2. PIPELINE
DRUGS
3.2. BY
DISEASE STAGE
3.2.1. LATE
STAGE: SEVERE AD
3.2.2. EARLY/MIDDLE
STAGE: MILD TO MODERATE AD
3.2.3. PRODROMAL
STAGE
3.3. BY
GENERIC & BRANDED
3.3.1. BRANDED
3.3.2. GENERIC
4. ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY DIAGNOSTICS
4.1. LUMBAR
PUNCTURE TEST
4.2. POSITRON
EMISSION TOMOGRAPHY
4.3. ELECTROENCEPHALOGRAPHY
4.4. MAGNETIC
RESONANCE IMAGING
4.5. COMPUTED
TOMOGRAPHY
4.6. BLOOD
TEST
4.7. OTHER
DIAGNOSTICS
5. ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – COUNTRY OUTLOOK
5.1. CHINA
5.2. JAPAN
5.3. INDIA
5.4. SOUTH
KOREA
5.5. ASEAN
COUNTRIES
5.6. AUSTRALIA
AND NEW ZEALAND
5.7. REST
OF ASIA-PACIFIC
6. COMPETITIVE
LANDSCAPE
6.1. BAXTER
INTERNATIONAL INC
6.2. F.
HOFFMANN-LA ROCHE AG
6.3. ALLERGAN
PLC (ACQUIRED BY ABBVIE)
6.4. NOVARTIS
AG
6.5. PFIZER
INC
6.6. SIEMENS
HEALTHINEERS AG
6.7. AMARANTUS
BIOSCIENCE HOLDINGS INC
6.8. EISAI
CO LTD
6.9. ELI
LILLY & COMPANY
6.10. LUPIN
LIMITED
6.11. MERCK
AND CO
6.12. BIOGEN
INC
6.13. COGNOPTIX
INC
6.14. GE
HEALTHCARE
6.15. JOHNSON
AND JOHNSON
6.16. SUN
PHARMACEUTICALS INDUSTRIES LTD
6.17. TEVA
PHARMACEUTICAL INDUSTRIES LTD
6.18. ZYDUS
CADILA
7. METHODOLOGY
& SCOPE
7.1. RESEARCH
SCOPE
7.2. SOURCES
OF DATA
7.3. RESEARCH
METHODOLOGY
TABLE LIST
TABLE
1: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET,
COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE
2: MARKET ATTRACTIVENESS MATRIX
TABLE
3: VENDOR SCORECARD
TABLE
4: KEY STRATEGIC DEVELOPMENTS
TABLE
5: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY
THERAPEUTICS, 2022-2028 (IN $ MILLION)
TABLE
6: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE,
2022-2028 (IN $ MILLION)
TABLE
7: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE,
2022-2028 (IN $ MILLION)
TABLE
8: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC &
BRANDED, 2022-2028 (IN $ MILLION)
TABLE
9: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY
DIAGNOSTICS, 2022-2028 (IN $ MILLION)
TABLE
10: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET,
COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
FIGURE LIST
FIGURE
1: PORTER’S FIVE FORCES ANALYSIS
FIGURE
2: KEY IMPACT ANALYSIS
FIGURE
3: TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS
FIGURE
4: INDUSTRY COMPONENTS
FIGURE
5: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY
THERAPEUTICS, 2021 & 2028 (IN %)
FIGURE
6: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2021
& 2028 (IN %)
FIGURE
7: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS,
2022-2028 (IN $ MILLION)
FIGURE
8: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS,
2022-2028 (IN $ MILLION)
FIGURE
9: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2021
& 2028 (IN %)
FIGURE
10: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE STAGE: SEVERE
AD, 2022-2028 (IN $ MILLION)
FIGURE
11: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE
STAGE: MILD TO MODERATE AD, 2022-2028 (IN $ MILLION)
FIGURE
12: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE,
2022-2028 (IN $ MILLION)
FIGURE
13: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC &
BRANDED, 2021 & 2028 (IN %)
FIGURE
14: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2028
(IN $ MILLION)
FIGURE
15: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2028
(IN $ MILLION)
FIGURE
16: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY
DIAGNOSTICS, 2021 & 2028 (IN %)
FIGURE
17: ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE
TEST, 2022-2028 (IN $ MILLION)
FIGURE
18: ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION
TOMOGRAPHY, 2022-2028 (IN $ MILLION)
FIGURE
19: ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY
ELECTROENCEPHALOGRAPHY, 2022-2028 (IN $ MILLION)
FIGURE
20: ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE
IMAGING, 2022-2028 (IN $ MILLION)
FIGURE
21: ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED
TOMOGRAPHY, 2022-2028 (IN $ MILLION)
FIGURE
22: ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST,
2022-2028 (IN $ MILLION)
FIGURE
23: ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS,
2022-2028 (IN $ MILLION)
FIGURE
24: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET,
COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE
25: CHINA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2022-2028
(IN $ MILLION)
FIGURE
26: JAPAN ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2022-2028
(IN $ MILLION)
FIGURE
27: INDIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2022-2028
(IN $ MILLION)
FIGURE
28: SOUTH KOREA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET,
2022-2028 (IN $ MILLION)
FIGURE
29: ASEAN COUNTRIES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET,
2022-2028 (IN $ MILLION)
FIGURE
30: AUSTRALIA & NEW ZEALAND ALZHEIMER’S DISEASE THERAPEUTICS AND
DIAGNOSTICS MARKET, 2022-2028 (IN $ MILLION)
FIGURE
31: REST OF ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET,
2022-2028 (IN $ MILLION)
R&D efforts and numerous
clinical trials are expected to foster the market growth in Japan
MARKET OUTLOOK
A
Triton Market Research report states that the Alzheimer’s disease therapeutics
and diagnostics market in the Asia-Pacific would fast progress with a CAGR of
12.18% over the forecast duration from 2022 to 2028. Japan, India, South Korea,
China, Australia & New Zealand, ASEAN countries, and Rest of Asia-Pacific are
assessed in the market in this region.
South
Korea’s population is aging rapidly. The number of people aged 65 years or
above is predicted to reach 12.658 million (24.7%) by 2030, as per the World
Population Ageing 2019 study. Due to the rising elderly population’s increased
susceptibility to neurological illnesses, including Alzheimer’s disease, the
demand for its therapeutics and diagnostics is expected to surge. As a result,
the Alzheimer’s disease therapeutics and diagnostics market in the country is
anticipated to experience growth during the forecast period.
The
Japanese market for Alzheimer’s disease diagnostics and therapeutics is also
anticipated to grow favorably over the forecast period, thanks to a strong
healthcare system to meet the demands of the rapidly growing geriatric
population suffering from dementia, as well as effective public policies and dedicated
research for introducing novel treatments. R&D activities for Alzheimer’s
detection are in full swing, as the overall understanding of the disease
pathology has also gained significant momentum in the last few years. The
National Clinical Trials Registry (NCT) reports that, there are roughly 15
ongoing clinical trials for Alzheimer’s disease across various phases at
present, in the country. Such developments are expected to foster the market’s growth.
Get more insights the
Asia-Pacific Alzheimer’s Disease
Therapeutics And Diagnostic Market:
COMPETITIVE OUTLOOK
The
prominent companies in the Alzheimer’s disease therapeutics and diagnostics
market are Cognoptix Inc, Eli Lilly & Company, Novartis AG, GE Healthcare,
Pfizer Inc, Eisai Co Ltd, F. Hoffmann-La Roche AG, Baxter International Inc,
and Sun Pharmaceuticals Industries Ltd.
SEGMENTATION
1. BAXTER
INTERNATIONAL INC
2. F.
HOFFMANN-LA ROCHE AG
3. ALLERGAN
PLC (ACQUIRED BY ABBVIE)
4. NOVARTIS
AG
5. PFIZER
INC
6. SIEMENS
HEALTHINEERS AG
7. AMARANTUS
BIOSCIENCE HOLDINGS INC
8. EISAI
CO LTD
9. ELI
LILLY & COMPANY
10. LUPIN
LIMITED
11. MERCK
AND CO
12. BIOGEN
INC
13. COGNOPTIX
INC
14. GE
HEALTHCARE
15. JOHNSON
AND JOHNSON
16. SUN
PHARMACEUTICALS INDUSTRIES LTD
17. TEVA
PHARMACEUTICAL INDUSTRIES LTD
18. ZYDUS
CADILA
Comments
Post a Comment